Brielle Benyon, Assistant Managing Editor for CURE®, has been with MJH Life Sciences since 2016. She has served as an editor on both CURE and its sister publication, Oncology Nursing News. Brielle is a graduate from The College of New Jersey. Outside of work, she enjoys spending time with family and friends, CrossFit and wishing she had the grace and confidence of her toddler-aged daughter.
Follow Brielle on Twitter @Brielle_Benyon.
Darzalex Combination Granted Priority Review for Myeloma Treatment
January 22nd 2018The Food and Drug Administration (FDA) granted priority review to the combination use of Darzalex (daratumumab), Velcade (bortezomib), melphalan and prednisone for the treatment of newly diagnosed patients with multiple myeloma who are not eligible for autologous stem cell transplant (ACST).
Leukemia Research Foundation Accelerates Research, Hope in Blood Cancers
January 19th 2018While the treatment of leukemia has greatly advanced since 1946, so has the organization. In the past seven decades, LRF has raised more than $75 million for its mission of conquering not only leukemia, but all blood cancers.
Burning the Midnight Oil: Night Shift Work May Increase Cancer Risk
January 19th 2018Research constantly highlights how adequate sleep impacts health outcomes. A recent meta-analysis, published in Cancer Epidemiology, Biomarkers & Prevention, delved in a bit further to see if people who stayed up all night for work had an increased chance of developing cancer.
Monitoring for AML Remissions: Are We Measuring Properly?
January 18th 2018So, wouldn't it be nice to have a quantitative way to say how deep the remission is? Historically, it’s been felt that if you just scratch the surface and get below the 5 percent blast level, you’re probably going to relapse. And if you get deeper, you might not.
Molecular Testing Is Key in Understanding MSI-H Colorectal Cancer
January 16th 2018In recent years, next-generation sequencing has allowed physicians and researchers alike to gather more genetic data for patients with gastrointestinal cancers. And while this kind of profiling continues to advance, so do treatment options for this patient population.
Personalized Care Plans Must Consider Social Disparities
January 11th 2018Racial and socioeconomic status disparities can affect all types of lung cancer treatment – including surgery, chemotherapy and radiation. However, researchers may not be aware of this, since many of these groups are underrepresented in lung cancer clinical trials.
Combinations May Be the Future of Immunotherapy in Ovarian Cancer
January 10th 2018To date, trials testing the use of immunotherapy in the treatment of ovarian cancer yielded disappointing results. However, researchers are not giving up. Instead, they’re investigating to see if immunotherapy drugs – such as PD1 and PDL-1 inhibitors – can be combined with other agents to benefit patients.
Popular Myeloma Drug Associated With Higher Rates of Heart Toxicity
January 5th 2018A drug commonly used to treat patients with multiple myeloma may lead to an increased risk of cardiovascular events such as heart attacks, according to recent research conducted at the Abramson Cancer Center of the University of Pennsylvania.
Inner-Ear Buildup of Cisplatin May Cause Hearing Loss
January 5th 2018“As the population of cancer survivors continues to grow, so does the importance of addressing the long-term sequelae of cancer treatment,” the authors wrote. “This hearing loss can result in multifaceted decrease in quality of life, and in pediatric patients it can impact social and academic development.”
CLL Survivors Worried About Life Expectancy, Quality of Life
December 25th 2017While patients with chronic lymphocytic leukemia (CLL) tend to have long life expectancies, with many prescribed to a “watch-and-wait” approach, a recent study by the Cancer Support Community (CSC) found that more than half of patients living with the disease reported that having CLL affects their viewpoints regarding their life expectancy.
Optune Combination Improves Survival in Glioblastoma
December 21st 2017Optune is a method of treatment where adhesive patches are applied to the patient’s scalp. The patch transductors deliver low-intensity electric fields – called Tumor Treating Fields – that stop the growth and division of GBM cells.
The FDA Is Cracking Down on Risky Homeopathic Drugs
December 19th 2017Many patients with cancer choose to use homeopathic therapies either in addition to, or in lieu of traditional treatments. However, since these agents don’t go through the same FDA approval process as typical drugs, patients may be subject to harmful effects.
FDA Warns Against Surgery That Can Spread Uterine Cancer
December 15th 2017Women with presumed uterine growths known as fibroids who underwent laparoscopic power morcellation (LPM) have higher rates of uterine cancer recurrence and worse outcomes compared to those who got manual or no morcellation, according to a recent release published by the Food and Drug Administration.
Empowering Patients and Advocates Through Breast Cancer Education
December 14th 2017Hoping that other women did not have to go through what she went through, in 1993 she co-founded the Alamo Breast Cancer Foundation (ABCF), a grassroots organization that helps patient advocates become educated on the disease – ultimately leading to more informed treatment decisions.
The Leukemia & Lymphoma Society Offers Research, Advocacy and Patient Support
December 14th 2017When it comes to advancements in treating blood cancers, 2017 was a particularly exciting year, with well over a dozen new therapies or indications approved by the Food and Drug Administration (FDA). The Leukemia & Lymphoma Society has played a role in at least 10 of these new drugs or medication uses at some point throughout their development and approval process.
Interdisciplinary Teams Can Help Decrease Hospital Readmissions
December 13th 2017Hospital readmissions soon after discharge can be costly and detrimental to patient care, but according to a recent study conducted at the Cleveland Clinic and presented at the 2017 American Society of Hematology’s Annual Meeting and Exposition, creating an interdisciplinary team to work with patients can help.
Young Breast Cancer Survivors Empowered Through Advocacy and Education
December 11th 2017“It was frustrating always being the youngest one in the waiting room, combined with the fact that there is just not a lot of data on this population. So, we are forced to make decisions in the absence of hard data. It’s frustrating to know that we’re the neglected cohort of the disease,” Petrides said.
Addressing the Psychosocial Side of Childhood Cancer
December 8th 2017The Mattie Miracle Cancer Foundation is dedicated to addressing the psychological needs of children and families with childhood cancer. It also aims to educate health care providers about potential psychosocial effects of a diagnosis.